Compare XZO & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XZO | NVCR |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | XZO | NVCR |
|---|---|---|
| Price | $16.67 | $13.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $27.00 | ★ $28.08 |
| AVG Volume (30 Days) | 172.3K | ★ 2.6M |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $56.84 | $6.14 |
| Revenue Next Year | $13.24 | $11.72 |
| P/E Ratio | $18.63 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $12.92 | $9.82 |
| 52 Week High | $24.60 | $21.55 |
| Indicator | XZO | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 58.30 |
| Support Level | $13.52 | $12.66 |
| Resistance Level | $19.36 | $14.13 |
| Average True Range (ATR) | 1.25 | 1.11 |
| MACD | 0.17 | 0.40 |
| Stochastic Oscillator | 71.85 | 68.26 |
Exzeo Group Inc provides turnkey insurance technology and operations solutions to insurance carriers and their agents based on a proprietary platform of purpose-built software and data analytics applications that are specifically designed for the property and casualty, or P&C, insurance ecosystem. Its Insurance-as-a-Service (IaaS) platform, which it refers to as the Exzeo Platform, currently includes nine configurable software and data analytics applications that are purpose-built to serve insurance companies and other customers in the insurance value chain. Through the Exzeo Platform, the company provides technology-based solutions and services for all operational and administrative activities and functions needed by P&C insurance carriers and their agents.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.